Alnylam Pharmaceuticals Stock Forecast, Price & News

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 8 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Alnylam Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALNY, but not buy additional shares or sell existing shares.
View analyst ratings for Alnylam Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Alnylam Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Alnylam Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Alnylam Pharmaceuticals saw a increase in short interest in July. As of July 30th, there was short interest totaling 5,060,000 shares, an increase of 19.9% from the July 15th total of 4,220,000 shares. Based on an average daily trading volume, of 653,200 shares, the short-interest ratio is currently 7.7 days.
View Alnylam Pharmaceuticals' Short Interest.

Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its quarterly earnings data on Monday, August, 2nd. The biopharmaceutical company reported ($1.61) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($1.61). The biopharmaceutical company earned $220.55 million during the quarter, compared to the consensus estimate of $193.66 million. Alnylam Pharmaceuticals had a negative net margin of 128.96% and a negative trailing twelve-month return on equity of 88.43%. The firm's quarterly revenue was up 112.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.67) EPS.
View Alnylam Pharmaceuticals' earnings history.

Alnylam Pharmaceuticals' stock was trading at $101.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALNY stock has increased by 86.7% and is now trading at $190.20.
View which stocks have been most impacted by COVID-19.

Alnylam Pharmaceuticals updated its FY 2021 earnings guidance on Tuesday, August, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $790 million-$865 million, compared to the consensus revenue estimate of $837.45 million.

15 analysts have issued 12 month target prices for Alnylam Pharmaceuticals' shares. Their forecasts range from $47.00 to $250.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $169.33 in the next twelve months. This suggests that the stock has a possible downside of 11.0%.
View analysts' price targets for Alnylam Pharmaceuticals or view top-rated stocks among Wall Street analysts.

65 employees have rated Alnylam Pharmaceuticals CEO John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among Alnylam Pharmaceuticals' employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Exact Sciences (EXAS), Novavax (NVAX), Incyte (INCY), Repligen (RGEN), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of ALNY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Alnylam Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (14.84%), Vanguard Group Inc. (8.83%), Baillie Gifford & Co. (8.70%), BlackRock Inc. (7.32%), Price T Rowe Associates Inc. MD (4.65%) and Dodge & Cox (4.56%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, Jeffrey W Dunn, John Maraganore, Laurie Keating, Marsha Fanucci, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet.
View institutional ownership trends for Alnylam Pharmaceuticals.

ALNY stock was sold by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., Point72 Asset Management L.P., BlackRock Inc., APG Asset Management N.V., Invesco Ltd., Blackstone Inc, Bridger Management LLC, and Vanguard Group Inc.. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Jeffrey W Dunn, John Maraganore, Laurie Keating, Phillip A Sharp, Steven M Paul, and Yvonne Greenstreet.
View insider buying and selling activity for Alnylam Pharmaceuticals or view top insider-selling stocks.

ALNY stock was acquired by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Dodge & Cox, Ikarian Capital LLC, Amundi, Balyasny Asset Management LLC, State Street Corp, The Manufacturers Life Insurance Company , and Baillie Gifford & Co..
View insider buying and selling activity for Alnylam Pharmaceuticals or or view top insider-buying stocks.

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALNY stock can currently be purchased for approximately $190.20.

Alnylam Pharmaceuticals has a market capitalization of $22.60 billion and generates $492.85 million in revenue each year. The biopharmaceutical company earns $-858,280,000.00 in net income (profit) each year or ($7.46) on an earnings per share basis.

Alnylam Pharmaceuticals employs 1,453 workers across the globe.

Alnylam Pharmaceuticals was founded in 2002.

The official website for Alnylam Pharmaceuticals is www.alnylam.com.

Alnylam Pharmaceuticals is headquartered at 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142.

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at (617) 551-8200 or via email at [email protected]